Nanobody-based anti-CD5 CAR T agent improves efficacy in relapsed or refractory T-cell ALL
The nanobody-based CD5 CAR T-cells had superior antigen-dependent activation compared with humanized CD5 CAR T-cells, said lead author, Jing Pan, MD, PhD, of
EHA 2026
Cellular Therapy
Leukemia
Acute Lymphoblastic Leukemia
Meetings / Conferences
EHA 2026
Multiple Myeloma
MajesTEC-3 trial post-hoc analysis: Teclistamab regimen boosts survival across risk in myeloma
The MajesTEC-3 trial compared teclistamab plus daratumumab with standard daratumumab plus dexamethasone and pomalidomide or bortezomib (DPd/DVd). In the previous primary analysis, teclistamab
EHA 2026
Meetings / Conferences
Myeloproliferative Neoplasms
Primary Myelofibrosis
Novel germline JAK2 mutation linked to progression to MF in MPN
The analysis reviewed clinical data and samples from patients with MPN diagnosed at the authors’ center from 2018 to 2025 to characterize the
EHA 2026
Meetings / Conferences
Myeloproliferative Neoplasms
Primary Myelofibrosis
ERNEST-3 analysis characterizes prevalence of cytopenic MF and treatment trends
The analysis included 418 patients diagnosed with MF between January 2018 and January 2026 at 21 European centers. At time of diagnosis, 232
ASCO 2026
Cellular Therapy
Multiple Myeloma
News
Anito-cel manufacturing builds on CAR T-cell learnings in multiple myeloma trials
The anito-cel analysis covered 104 patients enrolled and leukapheresed in iMMagine-3 or GEM-AnitoFirst from September 2024 to October 2025. Anito-cel lots were successfully
ASCO 2026
Lymphoma
Aggressive B-Cell Lymphomas
Frontline tafasitamab, lenalidomide plus R-CHOP improves outcomes in B-cell lymphomas
Tafa-Len-R-CHOP represents a potential new first-line standard of care for patients with high-risk DLBCL or high-grade B-cell lymphoma, regardless of cell of origin
ASCO 2026
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Lymphoma
T-Cell Lymphoma
Meetings / Conferences
Oncologist migration patterns in the US may drive geographical care disparities
Oncologist migration patterns in the US may drive geographical care disparities, according to a poster presented at ASCO 2026.
ASCO 2026
Lymphoma
Aggressive B-Cell Lymphomas
Meetings / Conferences
Golcadomide improves first-line treatment for aggressive B-cell lymphoma
First-line treatment with golcadomide, a first-in-class oral cereblon E3 ligase modulator, plus Pola-RCHP resulted in predictable and manageable safety outcomes without compromising Pola-RCHP